What is the primary reason for the year-over-year decline in Gilead's total revenues?

The primary reason for the 22% year-over-year decline in total revenues for the first quarter of 2018 is the significant decrease in Hepatitis C (HCV) product sales. HCV product sales fell by 59% to $1.0 billion, driven by increased competition and a market shift away from older treatments like Harvoni and Sovaldi.

How is Gilead's HIV and HBV business performing?

Gilead's HIV and HBV product sales showed resilience, increasing by 2% to $3.3 billion. This growth was primarily attributed to the strong uptake of newer Descovy-based regimens, including Biktarvy, Descovy, Genvoya, and Odefsey, as patients transition away from older Truvada-based products.

What is the financial impact of the Kite Pharma acquisition mentioned in the filing?

The acquisition of Kite Pharma, completed in October 2017, is reflected in the financial statements. Research and development (R&D) and Selling, General, and Administrative (SG&A) expenses increased due to stock-based compensation related to the acquisition. The acquisition also resulted in significant intangible assets and goodwill recorded on the balance sheet, with ongoing efforts to finalize their valuation. The company also repaid $4.5 billion in term loans related to the acquisition during the quarter.

What are the key legal risks highlighted in this report?

Gilead faces numerous legal risks, primarily related to patent litigation concerning its key products like sofosbuvir (Sovaldi), axicabtagene ciloleucel (Yescarta), and bictegravir (Biktarvy). These involve disputes with competitors like Merck and ViiV Healthcare, as well as challenges from generic manufacturers seeking to market their versions of Gilead's drugs. Additionally, the company is subject to ongoing government investigations related to its marketing practices, pricing, and support programs.

GILD 10-Q Quarterly Report Q1 FY2018 — Revenue, Net Income, EPS

Summary

Gilead Sciences reported first-quarter 2018 revenues of $5.1 billion, a decrease of 22% year-over-year, primarily driven by a significant decline in Hepatitis C (HCV) product sales. While HIV and Hepatitis B (HBV) product sales saw a modest increase due to the strong performance of Descovy-based regimens, the sharp drop in HCV sales, particularly Harvoni and Sovaldi, overshadowed this growth. The company is actively managing a complex legal landscape, with ongoing patent disputes and government investigations presenting potential risks. Despite the revenue decline, Gilead generated substantial operating cash flow of $2.3 billion. The company also repaid $4.5 billion in term loans and continued its share repurchase program, demonstrating a commitment to returning capital to shareholders. Management acknowledges the expected decline in HCV sales for the full year 2018 due to increased competition and is focusing on the growth of its HIV franchise, particularly with the recent launch of Biktarvy.

Financial Highlights

57 data points

Beta

Revenue

$5.09B

0.8% Gross Margin

Net Income

$1.54B

0.3% Net Margin

EPS (Diluted)

$1.17

Total Assets

$65.38B

Cash & Equivalents

$7.64B

Free Cash Flow

$2.06B

Financial Statements

Beta

Revenue	$5.09B
Cost of Revenue	$1.00B
Gross Profit	$4.00B
R&D Expenses	$937.00M
SG&A Expenses	$997.00M
Operating Expenses	$2.94B
Operating Income	$2.15B
Interest Expense	$290.00M
Net Income	$1.54B
EPS (Basic)	$1.18
EPS (Diluted)	$1.17
Shares Outstanding (Basic)	1.31B
Shares Outstanding (Diluted)	1.32B

Key Highlights

1Total revenues for Q1 2018 were $5.1 billion, a 22% decrease compared to $6.5 billion in Q1 2017, primarily due to lower product sales.
2Product sales declined 22% to $5.0 billion in Q1 2018 from $6.4 billion in Q1 2017, mainly driven by a 59% decrease in HCV product sales to $1.0 billion.
3HIV and HBV product sales increased 2% to $3.3 billion, fueled by the uptake of Descovy-based products like Biktarvy and Genvoya.
4Net income attributable to Gilead decreased to $1.5 billion ($1.17 per diluted share) in Q1 2018, down from $2.7 billion ($2.05 per diluted share) in Q1 2017, largely due to lower product sales.
5The company generated $2.3 billion in operating cash flow in Q1 2018 and fully repaid $4.5 billion in term loans.
6Gilead repurchased approximately $1.0 billion of its common stock during the quarter and had $7.0 billion remaining under its stock repurchase program as of March 31, 2018.
7The company adopted new revenue recognition standards (Topic 606) effective January 1, 2018, with a modified retrospective approach.

GILEAD SCIENCES, INC. Quarterly Report for Q1 Ended Mar 31, 2018

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions